**PATENT ASSIGNMENT**

Electronic Version v1.1  
Stylesheet Version v1.1

<table>
<thead>
<tr>
<th>SUBMISSION TYPE:</th>
<th>NEW ASSIGNMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grant of a Security Interest in Grantor's (Debtor's) Ownership Rights to Grantee (Secured Party)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NATURE OF CONVEYANCE:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pharming Intellectual Property B.V. 02/23/2006</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RECEIVING PARTY DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: King George Holdings Luxembourg IIA S.A.R.L.</td>
</tr>
<tr>
<td>Street Address: 174 Route de Longwy</td>
</tr>
<tr>
<td>City: Luxembourg</td>
</tr>
<tr>
<td>State/Country: LUXEMBOURG</td>
</tr>
<tr>
<td>Postal Code: L-1940</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROPERTY NUMBERS Total: 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property Type</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Patent Number:</td>
</tr>
<tr>
<td>Patent Number:</td>
</tr>
<tr>
<td>Patent Number:</td>
</tr>
<tr>
<td>Patent Number:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CORRESPONDENCE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fax Number: (703)816-4100</td>
</tr>
<tr>
<td>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</td>
</tr>
<tr>
<td>Phone: 703-816-4057</td>
</tr>
<tr>
<td>Email: <a href="mailto:wfg@nixonvan.com">wfg@nixonvan.com</a></td>
</tr>
<tr>
<td>Correspondent Name: Willem F. Gadiano</td>
</tr>
<tr>
<td>Address Line 1: NIXON &amp; VANDERHYE P.C.</td>
</tr>
<tr>
<td>Address Line 2: 901 North Glebe Road, 11th Floor</td>
</tr>
<tr>
<td>Address Line 4: Arlington, VIRGINIA 22309</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ATTORNEY DOCKET NUMBER:</th>
<th>4379-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME OF SUBMITTER:</td>
<td>Willem F. Gadiano</td>
</tr>
</tbody>
</table>
UCC FINANCING STATEMENT

FOLLOW INSTRUCTIONS, FILL IN AND SIGN CAREFULLY

A. NAME & PHONE OF CONTACT AT FILER (optional)
   Yuko Yamakawa 415-268-6267

B. SEND ACKNOWLEDGMENT TO: (Name and Address)
   Please return copy to:
   CT CORPORATION SYSTEMS/UCC
   Att: Jeanie Parscale
   1350 Treat Blvd. Suite 100
   Walnut Creek CA 94597-2152
   1-800-874-8820 Ref# 896

C. DEBTOR'S EXACT FULL LEGAL NAME — must only contain letters and numbers (1 to 150 characters, not case-sensitive)
   Pharmaing Intellectual Property B.V.

D. ORGANIZATION NAME
   Pharmaing Intellectual Property B.V.

E. INDIVIDUAL'S LAST NAME
   First Name
   Middle Name
   Suffix

F. MAILING ADDRESS
   P.O. Box 451
   Leiden
   NL

G. ADDRESSES
   ADR: IPOR
   B.V.
   The Netherlands
   N/A

H. ADDITIONAL DEBTOR'S EXACT FULL LEGAL NAME — must only contain letters and numbers (1 to 150 characters, not case-sensitive)
   None

I. ORGANIZATIONS NAME
   None

J. INDIVIDUAL'S LAST NAME
   First Name
   Middle Name
   Suffix

K. MAILING ADDRESS
   City
   Postal Code
   Country

L. ADDRESSES
   ADR: IPOR
   B.V.
   The Netherlands
   N/A

M. JURISDICTION OF ORGANIZATION
   The Netherlands
   N/A

N. ORGANIZATIONAL UNIT OR ENTITY
   None

O. SECURED PARTY'S NAME (must only contain letters and numbers (1 to 150 characters, not case-sensitive)
   King George Holdings Luxembourg IIA S.A.R.L.

P. INDIVIDUAL'S LAST NAME
   First Name
   Middle Name
   Suffix

Q. MAILING ADDRESS
   174 Route de Longwy
   Luxembourg
   LU

R. JURISDICTION OF ORGANIZATION
   Luxembourg
   LU

S. ORGANIZATIONAL UNIT OR ENTITY
   None

4. This FINANCING STATEMENT covers the following collateral:
   Please see attached Schedule 1.

5. This FINANCING STATEMENT covers the following collateral:
   Please see attached Schedule 1.

6. ALTERNATIVELY DESIGNATION (if present)
   None

7. ADDITIONAL INFORMATION
   None

8. OPTIONAL FILER REFERENCE DATA
   Filed with: DC - District of Columbia Client Ref#60435.1
   F#151215
   A#241181

FILING OFFICE COPY -- UCC FINANCING STATEMENT (FORM UCC) (REV. 05/22/2020)
Debtor: Pharming Intellectual Property B.V.

Secured Party: King George Holdings Luxembourg IIA S.A.R.L.

**SCHEDULE 1 TO FINANCING STATEMENT**

This Financing Statement covers all of the Debtor's right, title and interest in, to and under the following property, in each case whether now or hereafter existing or arising or in which the Debtor now has or hereafter owns, acquires or develops an interest and wherever located, constituting Specified IP Assets (collectively, the “Collateral”):

(i) all patents and patent applications, domestic or foreign, all licenses relating to or under any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such patents and patent applications as described in the Schedules to the License Agreement), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

(ii) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks, domain names and trade names, all licenses relating to or under any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such marks, names and applications as described in the Schedules to the License Agreement), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsepted use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

(iii) all of Debtor's present and future United States, whether statutory or common law, registered or unregistered, now or hereafter in force throughout the world, including Debtor’s United States registered copyrights and copyright registrations listed in the Schedules to the License Agreement, all of Debtor’s present and future, United States applications for copyright registrations, including Debtor’s United States applications for copyright registrations listed in the Schedules to the License Agreement, and all of Debtor’s present and future copyrights which are unregistered or not yet registered in the Copyright Office (collectively, the “Copyrights”), and any and all royalties, payments, and other amounts payable to Debtor in connection with the Copyrights, together with all renewals and extensions of the Copyrights, the right to recover for all past, present, and future infringements of the Copyrights, and all computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying or incorporating the Copyrights, and all other rights of every kind whatsoever accruing thereunder or pertaining thereto;

(iv) the entire goodwill of or associated with the businesses now or hereafter conducted by the Debtor connected with and symbolized by any of the aforementioned properties and assets;

(v) all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;
(vi) all accounts, all intangible intellectual or other similar property and other
general intangibles associated with or arising out of any of the aforementioned properties and
assets and not otherwise described above, including all license payments and payments under
insurance (whether or not the Secured Party is the loss payee thereof) or any indemnity, warranty
or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing
Collateral; and

(vii) all products, proceeds and supporting obligations of or with respect to any
and all of the foregoing Collateral.

As used herein, “Specified IP Assets” means the C1-Specific Assets and the
Shared Assets as defined in the Licensing and Strategic Partnering Agreement, dated as of
February 2, 2006, as amended, modified, renewed or extended from time to time, by and among
Debtor, Pharming Group N.V. and Pharming Technologies B.V., and Secured Party, as investor.
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>TITLE</th>
<th>GRANT NO.</th>
<th>GRANT DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>DNA SEQUENCES TO TARGET PROTEINS TO THE MAMMARY GLAND FOR EFFICIENT SECRETION</td>
<td>5,304,489</td>
<td>19-Apr-1994</td>
</tr>
<tr>
<td>US</td>
<td>METHOD OF PRODUCING A TRANSGENIC BOVINE OR TRANSGENIC BOVINE EMBRYO</td>
<td>5,633,076</td>
<td>27-May-1997</td>
</tr>
</tbody>
</table>
Receipt# 631568

LARRY TODD
RECORER OF DEEDS
WASHINGTON, DC
20016
(202) 727-5374

Doc# 2006023848  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023849  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023850  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023851  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023852  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023853  Pgs: 1
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023854  Pgs: 2
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 40.00

Doc# 2006023855  Pgs: 3
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 70.00

Doc# 2006023856  Pgs: 3
Doc Type: FINANCING
Surchage  $ 6.50
UCCRecord  $ 70.00

Total  $ 478.50
Check Amt. Tendered  $ 478.50
Change Due  $ 0.00
Balance  $ 0.00

Total Documents: 9
Total Fees: 16

Client Name: CAPITOL DISTRICT INFORMATION, INC
Date: 02/21/2006 12:00:42 PM
Cashier: CASHIER7

RECORDED: 03/03/2006
PATENT
REEL: 017251 FRAME: 0070